IVIVI TECHNOLOGIES INC
OOTC:IVVI0.00
USD
+0.00
(+9,900.00%)
ISIN
US46589F1084
CUSIP
46589F108
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
0.00
81.12
5Y
-90.00
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Northvale United States
- IPO Date
- Oct 19, 2006
- Similar Companies
- Business
- Ivivi Technologies, Inc. is a medical technology company that designs, develops, and commercializes non-invasive electrotherapeutic medical devices and proprietary targeted pulsed electromagnetic field (tPEMF) systems for wound care, inflammation reduction, and pain management. The company's product and service portfolio includes the SofPulse non-invasive electrotherapy device, engineered for the palliative treatment of post-operative pain and edema in superficial soft tissue; the Roma and Roma3 electrotherapeutic systems, designed to accelerate the healing of chronic wounds and tissue injuries; the Torino II portable, battery-operated therapeutic device for clinical and home care administration; the ACTIVI high-frequency electromagnetic therapy apparatus; proprietary electroceutical waveform technologies configured to stimulate cellular signaling and soft tissue recovery; and related clinical research support, device maintenance, and intellectual property licensing services. Ivivi Technologies delivers its therapeutic solutions to hospitals, outpatient surgical centers, plastic and reconstructive surgery clinics, long-term acute care facilities, and home healthcare providers across the United States and select international markets. Founded in 1989, the company is headquartered in Montvale, New Jersey. In recent corporate developments, Ivivi Technologies transitioned its operating profile following strategic asset purchase agreements and intellectual property assignments that transferred commercial development and patent rights for its flagship SofPulse technology to specialized bio-health partners, while the company restructured its operational framework, pursued legacy patent and corporate administration, and migrated its equity trading to the over-the-counter (OTC) markets.